Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 13/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.42 |
| ▸ | USP2 | O75604 | 10/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | BCR | P11274 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19355284 | 0.87 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL20373149 | 0.87 | PRKDC (0.38) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL19355492 | 0.86 | NTRK1 (0.37) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL19355288 | 0.85 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL17634756 | 0.85 | PRKDC (0.45) | PIK3CAABL1BCRSLC40A1LRRK2 | |
| SCHEMBL19355128 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL19355476 | 0.85 | FAAH (0.42) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL19355460 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL19355473 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19CLK4USP2 | |
| SCHEMBL19355266 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19CLK4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057959-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | CYP1A2 2215/4885CYP3A4 1759/4885CYP2C19 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.